Supplementary Table S2 Sensitivity of MNR and PNA method

Variant (%)		Result				
	NR21	NR24	NR27	BAT25	BAT26	MSS/MSI-H
5%	_	_	_	_	_	MSS
10%	0	_	0	_	_	MSI-H
20%	0	0	0	0	0	MSI-H
40%	0	0	0	0	0	MSI-H
100%	0	0	0	0	0	MSI-H
Variant (%)		Result				
	NR21	NR24	NR27	BAT25	BAT26	MSS/MSI-H
1%	0	_	_	0	_	MSI-H
5%	0	0	0	0	0	MSI-H
10%	0	0	0	0	0	MSI-H
20%	0	0	0	0	0	MSI-H

Supplementary Table S3 MSI-H detection rate for each marker used in PNA and MNR method

Marker	PNA meth	od (n = 76)	MNR meth		
	Number of samples	Detection rate (%)	Number of samples	Detection rate (%)	p-value*
NR21	74	97.37%	71	93.42%	0.375
NR24	71	93.42%	64	84.21%	0.039
BAT26	71	93.42%	63	82.89%	0.077
BAT25	72	94.74%	72	94.74%	1
NR27	75	98.78%	74	97.37%	1

^{*} McNemar analysis was used to compare two different test results in the same cases.

Supplementary Table S4 Clinicopathologic characteristics of 76 MSI-H CRC patients and 90 MSS CRC patients

Clinicopathologi c factor	Classification	MSI-H (n=76)		MSS (n=90)		<i>p</i> -value*
Age, years		54.39	9±15.11	61.16	61.16±12.61	
Gender	Female	26	34.2%	34	37.8%	0.634
Gender	Male	50	65.8%	56	62.2%	
Location	Right side	53	69.7%	25	27.8%	<0.01
Location	Left side	23	30.3%	65	72.2%	
Pre OP CEA	≤5ng/ml	68	89.5%	61	67.8%	0.001
PIE OP CEA	>5ng/ml	8	10.5%	29	32.2%	
0 1	Non-exophytic	18	23.7%	35	38.9%	0.036
Gross type	Exophytic	58	76.3%	55	61.1%	
Size (cm)		6.1	3±2.8	4.43±2.05		<0.001
	Adenocarcinoma	63	82.9%	84	93.3%	0.031
Histologic	Mucinous adenocarcinoma	11	14.5%	5	5.6%	
diagnosis	Signet ring cell carcinoma	2	2.6%	0	0.0%	
	Neuroendocrine carcinoma	0	0.0%	1	1.2%	
	pT1	2	2.6%	10	11.1%	0.002
Tatana	pT2	13	17.1%	13	14.4%	
T stage	рТ3	57	75.0%	48	53.3%	
	pT4a and pT4b	4	5.3%	19	21.1%	

^{*} Fisher's exact test and Mann-Whitney test were used for the statistical analysis of categorical variables and continuous variables, respectively.

Supplementary Table S5 Clinicopathologic characteristics of patients with MSI-H CRCs associated with sporadic conditions or Lynch syndrome

Clinicopathologic factor	Classification	MSI-H CRCs associated with sporadic condition (n=67) 56.50±14.37		MSI-H CRCs associated with Lynch syndrome (n=9) 38.66±11.10		<i>p</i> -value*
Age, years						
Gender	Female	24	35.8%	2	22.2%	0.488
Gender	Male	43	64.2%	7	77.8%	
Location	Right side	49	73.1%	4	44.4%	0.119
Location	Left side	18	26.9%	5	55.6%	
Dr. OD OF A	≤5ng/ml	59	88.1%	8	88.9%	1
Pre OP CEA	>5ng/ml	8	11.9%	1	11.1%	
	Non-exophytic	16	23.9%	2	22.2%	1
Gross type	Exophytic	51	76.1%	7	77.8%	
Size		6.36	6±2.80	4.3	4±2.12	0.041
	Adenocarcinoma	56	83.6%	7	77.8%	0.321
Histologic diagnosis	Mucinous carcinoma	10	14.9%	1	11.1%	ĺ
ulagriosis	Signet ring cell carcinoma	1	1.5%	1	11.1%	
	pT1	2	3.0%	0	0.0%	0.644
+ .	pT2	11	16.4%	2	22.2%	ĺ
T stage	pT3	50	74.6%	7	77.8%	
	pT4a and pT4b	4	6.0%	0	0.0%	
Lymphovascular	Absent	50	75.8%	6	66.7%	0.684
invasion	Present	16	24.2%	3	33.3%	
	Absent	27	40.9%	5	42.7%	0.789
Mucin formation	Focal	30	45.5%	3	44.0%	
	Predominant	9	13.6%	1	13.3%	
Investor authors	Expanding	36	55.4%	4	44.4%	0.724
Invasion pattern	Infiltrative	29	44.6%	5	55.6%	
Crohn-like	Absent	25	38.5%	2	22.2%	0.472
reaction	Present	40	61.5%	7	77.8%	
Turne or burdeline	Absent	63	96.9%	8	88.9%	0.326
Tumor budding	Present	2	3.1%	1	11.1%	
	MLH1/PMS2 loss	42	62.7%	7	77.8%	1
	MSH2/MSH6 loss	15	22.4%	2	22.2%	
MMR protein	PMS2 loss	1	1.5%	0	0.0%	
expression by	MSH6 loss	5	7.5%	0	0.0%	
IHC	MLH1/PMS2/MSH2/MSH6 loss	1	1.5%	0	0.0%	
	MLH1/MSH2/MSH6 loss	1	1.5%	0	0.0%	

	MLH1/PMS2/MSH6 loss	1	1.5%	0	0.0%	
	No loss	1	1.5%	0	0.0%	
	NR21	65	97.00%	8	88.90%	0.319
Instablilty of MSI	NR24	63	94.00%	9	100%	1
makers in	BAT26	62	92.50%	9	100%	1
PNA-PCR	BAT25	64	95.50%	9	100%	1
	NR27	66	98.50%	9	100%	1
Instablilty of MSI makers in PCR-MNR	NR21	63	94.00%	9	100%	1
	NR24	55	82.10%	8	88.90%	1
	BAT26	54	80.60%	9	100%	0.344
	BAT25	63	94.00%	8	88.90%	0.477
	NR27	65	97.00%	9	100%	1

^{*} Fisher's exact test and Mann-Whitney test were used for the statistical analysis of categorical variables and continuous variables, respectively.

Supplementary Table S6 IHC-mediated MSI-H detection rate depending on the combination of markers and variable cut-off values for loss of MMR protein expression

	MSI-H detection rate (n = 76)							
Combination of MMR markers	Cut off value: complete loss			value: loss	Cut off value: ≥95% loss			
	Number of samples	Detection rate (%)	Number of samples	Detection rate (%)	Number of samples	Detection rate (%)		
MLH1	50	65.79%	50	65.79%	51	67.11%		
MSH2	15	19.74%	15	19.74%	19	25.00%		
PMS2	48	63.16%	51	67.11%	52	68.42%		
MSH6	8	10.53%	17	22.37%	25	32.89%		
MLH1 and MSH2	64	84.21%	64	84.21%	69	90.79%		
PMS2 and MSH6	56	73.68%	68	89.47%	75	98.68%		
MLH1, PMS2, MSH2, and MSH6	69	90.79%	73	96.05%	75	98.68%		